1477 Ocumension Therapeutics HKEX · China

Ocumension Therapeutics (1477) news

Ocumension Therapeutics is a public biotech or pharmaceutical company listed on HKEX under the ticker 1477, recorded under China. The directory classifies it as Biotechnology / therapeutics. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Ocumension Therapeutics news

We have not published a story on Ocumension Therapeutics yet. When there is news, it will appear here.

Questions about Ocumension Therapeutics

What is the ticker symbol of Ocumension Therapeutics?

Ocumension Therapeutics trades under the ticker 1477 on HKEX.

Where is Ocumension Therapeutics listed?

Ocumension Therapeutics is listed on HKEX.

Which country or territory is Ocumension Therapeutics listed under?

Our directory records Ocumension Therapeutics under China.

What does Ocumension Therapeutics do?

Our directory classifies Ocumension Therapeutics as: Biotechnology / therapeutics. This is a directory classification, not a description of the pipeline.

What is the ISIN of Ocumension Therapeutics?

The ISIN recorded for Ocumension Therapeutics is KYG674111011.

Does aibio.space cover Ocumension Therapeutics?

aibio.space lists Ocumension Therapeutics among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Ocumension Therapeutics?

Companies in our directory listed in the same country and business area as Ocumension Therapeutics: Beijing Konruns Pharmaceutical Co., Biocytogen Pharmaceuticals (Beijing) Co., Dizal Pharmaceutical Co, Xuanzhu Biopharmaceutical Co., Sunflower Pharmaceutical Group Co., China Medical System Holdings.

Investor discussion: Ocumension Therapeutics

Members talk about Ocumension Therapeutics (1477). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Ocumension Therapeutics, newest first. Each line links the filing it comes from.

Jun 8, 2026Financings
Share or debt issue: PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED ELECTION OF DIRECTOR; PROPOSED RE-APPOINTMENT OF AUDITOR; PROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT AND SERVICE PROVIDER SUBLIMIT; AND NOTICE OF ANNUAL GENERAL MEETING. Source
Apr 28, 2025Financings
Share or debt issue: PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED RE-APPOINTMENT OF AUDITOR; PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION; AND NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Ocumension Therapeutics's own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 20, 2026HKEXnews
INSIDE INFORMATION ANNOUNCEMENT TOPLINE RESULTS OF THE MONTH 36 PRIMARY ANALYSIS OF THE GLOBAL MULTI-CENTRE PHASE III CLINICAL TRIAL OF OT-101 (0.01% ATROPINE SULFATE EYE DROPS)
Sep 10, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF OT-301 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Sep 2, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-211
Sep 1, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF APPLICATION FOR DRUG REGISTRATION OF DOMESTICALLY PRODUCED DEXAMETHASONE INTRAOCULAR SUSPENSION
Aug 31, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-202
Aug 28, 2026HKEXnews
CHANGE IN USE OF PROCEEDS
Aug 28, 2026HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026
Jul 2, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF OT-502 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Jun 30, 2026HKEXnews
RESIGNATION OF CHIEF FINANCIAL OFFICER AND JOINT COMPANY SECRETARY AND CHANGE IN AUTHORIZED REPRESENTATIVE
Jun 30, 2026HKEXnews
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 30, 2026 AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES
Jun 8, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
Jun 8, 2026HKEXnews
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED ELECTION OF DIRECTOR; PROPOSED RE-APPOINTMENT OF AUDITOR; PROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT AND SERVICE PROVIDER SUBLIMIT; AND NOTICE OF ANNUAL GENERAL MEETING
May 28, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-802
May 12, 2026HKEXnews
GRANTS OF OPTIONS AND AWARDS
Apr 28, 2026HKEXnews
Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
Apr 28, 2026HKEXnews
Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
Mar 30, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-211
Mar 26, 2026HKEXnews
RETIREMENT AND PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
Mar 26, 2026HKEXnews
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Jan 19, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE REAL-WORLD STUDY OF OT-703 IN HAINAN BOAO

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:1477 on TradingView.

Listing details

Company: Ocumension Therapeutics
Ticker: 1477
Listing: HKEX
Country or territory: China
Business scope: Biotechnology / therapeutics
ISIN: KYG674111011
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction